Immuneering Corporation (IMRX) Return on equity 2021–2023
Immuneering Corporation (IMRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-59.0%FY2023 · since FY2021: -21.5% → -59.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -59.0% | -13.1 pp |
| FY2022 | -46.0% | -24.5 pp |
| FY2021 | -21.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More IMRX financial trends
IMRX RevenueIMRX Net incomeIMRX Net marginIMRX Gross profitIMRX Gross marginIMRX Operating incomeIMRX Operating marginIMRX Operating cash flowIMRX Free cash flowIMRX Capital expendituresIMRX Stock buybacksIMRX Dividends paidIMRX Total assetsIMRX Total liabilitiesIMRX Shareholders’ equityIMRX overview →